A Study of BOS-580 in Obese Subjects at Risk for, or With Biopsy-confirmed, Nonalcoholic Steatohepatitis (NASH) With an Extension

NCT04880031 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

231

Enrollment

INDUSTRY

Sponsor class

Conditions

Nonalcoholic Steatohepatitis (NASH)

Interventions

DRUG: Efimosfermin
DRUG: Placebo

Sponsor

Boston Pharmaceuticals

Collaborators

[object Object]